Cadila Healthcare's Company Signs 3 Share Purchase Agreements To Acquire Amplitude Surgical, Eyes Over 90 per cent Ownership Through Block Deal And Tender Offer Cadila Healthcare's Company Signs 3 Share Purchase Agreements To Acquire Amplitude Surgical, Eyes Over 90 per cent Ownership Through Block Deal And Tender Offer In a year, the stock has declined by 8 per cent while in last 3 years the stock has jumped by 151 per cent. DSIJ Intelligence-2 / Saturday, April 26, 2025 0 60 Article rating: 5.0 In a year, the stock has declined by 8 per cent while in last 3 years the stock has jumped by 151 per cent. Read more
Watch Out For These Penny Stocks Locked In The Upper Circuit on April 09, 2025 Watch Out For These Penny Stocks Locked In The Upper Circuit on April 09, 2025 Among all BSE-listed companies, 183 stocks were locked in the upper circuit, and 200 stocks were locked in the lower circuit. DSIJ Intelligence-2 / Wednesday, April 9, 2025 0 291 Article rating: 3.7 Read more
This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years With a PE ratio of 20x, the company trades at a discount compared to the industry PE of 28x. The company has ROCE of 22.3 per cent and ROE of 20.7 per cent. DSIJ Intelligence-2 / Monday, March 17, 2025 0 175 Article rating: 5.0 Read more
Zydus group Company Invests in Illexcor for Sickle Cell Treatment; Stock Gave 139.65 per cent in last 3 Years Zydus group Company Invests in Illexcor for Sickle Cell Treatment; Stock Gave 139.65 per cent in last 3 Years Over the past three years, the stock has delivered a substantial return of 139.65 per cent, classifying it as a multibagger stock. DSIJ Intelligence-2 / Thursday, March 13, 2025 0 161 Article rating: 5.0 Read more
New Drug Launch: Transforming Cardiometabolic Care in India New Drug Launch: Transforming Cardiometabolic Care in India Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India. DSIJ Intelligence-1 / Wednesday, March 12, 2025 0 241 Article rating: 5.0 The company continues to strengthen its presence in the cardiometabolic care segment, addressing the rising prevalence of diabetes and cardiovascular diseases in India. Read more